Ruohao Xu

Zunyi Medical University — China

Medicine · Health Sciences

6h-index104citations17works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(10), Myeloproliferative Neoplasms: Diagnosis and Treatment(4), Chronic Myeloid Leukemia Treatments(3), Mesenchymal stem cell research(2), Epigenetics and DNA Methylation(2)

Publications17 total

Advances in understanding the role of inflammatory factors and immune cells in the pathology of epilepsy, mediated by neuroimmune interactions within the gut-brain axis
Frontiers in Cell and Developmental Biology·2025· 1 citedOpen Access
Radial nerve injury secondary to screw compression following internal fixation for a midshaft humeral fracture: A case report
Asian Journal of Surgery·2025Open Access
MRD-Driven Prophylactic or Pre-Emptive Intervention with Chidamide-Based Treatment for High-Risk AML Relapse Post-Transplantation: A Real-World Experience from a Chinese Single Center
Blood·2024Open Access
TES and SLC40A1 as Potential Biomarkers for Predicting Survival in T-Cell Acute Lymphoblastic Leukemia
Acta Haematologica·2024· 1 cited
Multi-Omics Reveals Azacitidine Partially Restores Hematopoiesis-Supportive Functions in Mesenchymal Stromal Cells from Patients with Chronic Myelomonocytic Leukemia
Blood·2023
Mesenchymal stem cells reversibly de-differentiate myofibroblasts to fibroblast-like cells by inhibiting the TGF-β-SMAD2/3 pathway
Molecular Medicine·2023· 20 citedOpen Access
Multi-omics reveals azacitidine partially restores the hematopoiesis-supportive functions in mesenchymal stromal cells from patients with chronic myelomonocytic leukemia
2023Open Access
3055 – MULTI-OMICS REVEALS AZACITIDINE PARTIALLY RESTORES THE HEMATOPOIESIS-SUPPORTIVE FUNCTIONS IN MESENCHYMAL STROMAL CELLS FROM PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA
Experimental Hematology·2023Open Access
3054 – MESENCHYMAL STEM CELLS REVERSIBLY DE-DIFFERENTIATE MYOFIBROBLASTS TO FIBROBLAST-LIKE CELLS BY INHIBITING THE TGF-Β-SMAD2/3 PATHWAY
Experimental Hematology·2023
Decoding Emotional Valence from EEG in Immersive Virtual Reality
2022 Asia-Pacific Signal and Information Processing Association Annual Summit and Conference (APSIPA ASC)·2022· 4 cited
Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment
Frontiers in Immunology·2022· 8 citedOpen Access
Bone marrow mesenchymal stromal cells in chronic myelomonocytic leukaemia: overactivated WNT/β‐catenin signalling by parallel RNA sequencing and dysfunctional phenotypes
British Journal of Haematology·2021· 9 citedOpen Access
Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review
Hematology·2021· 6 citedOpen Access
Concurrence of Myelodysplastic syndromes and large granular lymphocyte leukemia: clinicopathological features, mutational profile and gene ontology analysis in a single center.
PubMed·2021· 8 citedOpen Access
Caspofungin combined with TMP/SMZ as a first‐line therapy for moderate‐to‐severe PCP in patients with human immunodeficiency virus infection
HIV Medicine·2020· 23 citedOpen Access
A retrospective study comparing azacitidine with decitabine in Chinese patients with refractory anemia with excess blast based on two clinical trials in a single center.
PubMed·2019· 4 citedOpen Access
Co-occurrence of RUNX1 and ASXL1 mutations underlie poor response and outcome for MDS patients treated with HMAs.
PubMed·2019· 20 citedOpen Access

Frequent Co-authors

Suxia Geng(12), Jianyu Weng(10), Peilong Lai(10), Ping Wu(9), Minming Li(9), Chengxin Deng(9), Xin Du(8), Lingji Zeng(5), Xin Huang(4), Zesheng Lu(3), Xiaomei Chen(3), Qihui Sun(2), Yawen Wang(2), Yulian Wang(2), Maozhi Xiao(2), Jianyu Weng(2), Xin Du(2), Qun Tian(1), Jing Si(1), Fan Jiang(1)